湯村千尚先生の症例報告論文が、Clinical J Gastroenterology（Journal Citation Reports Impact Factor 2024 = 0.9）にpublishされました。

Clin J Gastroenterol. 2025 Sep 8. doi: 10.1007/s12328-025-02218-8. Online ahead of print.

Crohn’s disease exacerbated by ghost pills of upadacitinib

Chihiro Yunomura, Shunsuke Kojimahara, Keiichi Tominaga, Kengo Matsumoto, Mimari Kanazawa, Takanao Tanaka, Akira Yamamiya, Takeshi Sugaya, Kenichi Goda, Atsushi Irisawa 1

Affiliations Expand
PMID: 40921994 DOI: 10.1007/s12328-025-02218-8

Abstract
The patient, a woman in her 40 s, was diagnosed with Crohn’s disease (CD) of the small and large intestine, for which she had been treated for 30 years. The disease activity was difficult to control with infliximab. She underwent multiple surgical procedures, including partial resection of the small intestine and colostomy. She was subsequently introduced to several biologic agents, including adalimumab, ustekinumab, and vedolizumab: All failed to maintain long-term endoscopic and clinical remission. She was introduced to upadacitinib (UPA), but her disease worsened because of the so-called ghost pill phenomenon, by which pills are ejected directly into a pouch through the colostomy because of her short bowel after surgery, which prevented therapeutic efficacy. When using an extended-release agent such as UPA in patients with CD, the patient’s gastrointestinal condition must be considered. Moreover, appropriate information must be shared with other health care professionals.

https://pubmed.ncbi.nlm.nih.gov/40921994/